Drug & intervention
darunavir
RxCUI 460132
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownInflammation and Co-Infections in D²EFTNCT04183738 · 2021-02-01
WITHDRAWNNucleosides And Darunavir/Dolutegravir In AfricaNCT03988452 · 2019-07-30
UNKNOWNDarunavir and Rilpivirine Interactions With Etonogestrel Contraceptive ImplantNCT03589040 · 2018-09-25
UNKNOWNDolutegravir and Darunavir Evaluation in Adults Failing TherapyNCT03017872 · 2017-11-23
UNKNOWNOptimization of Darunavir Therapy and Dosage RecommendationsNCT03101644 · 2017-03-23
COMPLETEDEvaluation of Low-dose Darunavir in a Switch StudyNCT02671383 · 2016-06-30
COMPLETEDA Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsNCT02578550 · 2015-11-01
COMPLETEDEffect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected IndividualsNCT02503462 · 2015-07-01
TERMINATEDRelative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationNCT02475135 · 2015-06-01
COMPLETEDCost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveNCT02470650 · 2015-06-01
WITHDRAWNEvaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 PatientsNCT02384967 · 2015-03-01
COMPLETEDEfficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionNCT02475915 · 2015-01-01
COMPLETEDSafety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)NCT02275780 · 2014-12-01
COMPLETEDA Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)NCT02277600 · 2014-11-05
COMPLETEDEvaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)NCT02116660 · 2014-09-03
TERMINATEDStudy in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500NCT02489487 · 2014-09-01
COMPLETEDEfficacy and Safety Study of Darunavir for the Treatment of HIV/AIDSNCT02155101 · 2014-05-01
COMPLETEDSecond-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneNCT01605084 · 2012-06-30
WITHDRAWNPharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or EfavirenzNCT01695954 · 2012-05-01
COMPLETEDA Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted ConditionsNCT01619527 · 2012-04-01
COMPLETEDA Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentNCT01448707 · 2012-03-15
COMPLETEDThe Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic StudyNCT01348763 · 2011-10-01
COMPLETEDTMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVNCT01281813 · 2011-08-08
COMPLETEDEffect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersNCT01374802 · 2011-06-01
COMPLETEDA Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsNCT01199939 · 2010-05-01
COMPLETEDDual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.NCT01258374 · 2010-05-01
COMPLETEDMaraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1NCT00993148 · 2010-05-01
COMPLETEDA Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenNCT00919854 · 2009-09-01
COMPLETEDDrug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy VolunteersNCT00936793 · 2009-07-06
COMPLETEDA Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected AdolescentsNCT00915655 · 2009-07-01
COMPLETEDStudy in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal TissueNCT00855088 · 2009-07-01
COMPLETEDImpact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular ParametersNCT00851799 · 2009-06-01
COMPLETEDComparative Study of Three NNRTI-Sparing HAART RegimensNCT00811954 · 2009-05-01
COMPLETEDStudy of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.NCT00849160 · 2009-05-01
COMPLETEDA Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant WomenNCT00855335 · 2009-04-09
COMPLETEDHIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and EtravirineNCT00855413 · 2009-03-01
TERMINATEDRaltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsNCT00677300 · 2009-01-01
COMPLETEDNNRTI/PI Toxicity Switch to Darunavir StudyNCT00765154 · 2008-10-01
TERMINATEDChanges in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received TreatmentNCT00757783 · 2008-10-01
COMPLETEDTMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.NCT00744887 · 2008-08-01
COMPLETEDConditions being studied
HIV Infections15HIV10HIV INFECTION3HIV-1 Infection3Acute HIV Infection2Healthy2HIV/AIDS2Hyperlipidemia2Acquired Immunodeficiency Syndrome (AIDS) Virus1AIDS1AIDS-related Dementia Complex1Antiretroviral Therapy Intolerance1Asthma1Contraception1Cytomegalovirus Infections1Healthy Participants1HIV-11HIV-1 Infections1HIV-infection1HIV-infection/Aids1
Research locations
MiamiFlorida, United States9Chapel HillNorth Carolina, United States7ChicagoIllinois, United States7Los AngelesCalifornia, United States7New YorkNew York, United States7St LouisMissouri, United States7BostonMassachusetts, United States6DallasTexas, United States6DurhamNorth Carolina, United States6HoustonTexas, United States6NewarkNew Jersey, United States6ParisFrance6
Leading sponsors
Janssen Sciences Ireland UC3Tibotec Pharmaceuticals, Ireland3Tibotec, Inc3Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections2Boehringer Ingelheim2Kirby Institute2Makerere University2Merck Sharp & Dohme LLC2National Institute of Allergy and Infectious Diseases (NIAID)2University of North Carolina, Chapel Hill2ANRS, Emerging Infectious Diseases1Bristol-Myers Squibb1Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida1Dallas VA Medical Center1French National Agency for Research on AIDS and Viral Hepatitis1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.